clinical trial · NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRASVS-7375cetuximab
brief summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
started
Jun 16, 2026
primary completion
Jun 1, 2027
completion
Dec 1, 2028
last updated
Aug 7, 2026
official title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol